pharmaceuticals

Cencora, Inc (NYSE:COR) on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment. U.S. Healthcare Solutions revenue was $68.3...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares are sinking after the company released its first-quarter results after Tuesday's closing bell. Here's a look at the details from the report.  The Details: Sarepta Therapeutics reported quarterly losses of $3.42 per share, which missed the analyst...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported first-quarter financial results after the market close on Monday. Here’s a look at the key highlights from the period. Q1 Revenue: $2.77 billion versus estimates of $2.85 billion Q1 EPS: $4.06, versus estimates of $4.32 Total revenue grew...

Axsome Therapeutics Inc (NASDAQ:AXSM) on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million. Auvelity (oral antidepressant) net product sales for the quarter were $96.2 million, up 80% year over year....

Amneal Pharmaceuticals Inc. (NASDAQ:AMRX) reported first-quarter 2025 adjusted EPS of 21 cents, up from 14 cents a year ago, and beating the consensus of 15 cents. The company reported sales of $695.42 million, up 5% year-over-year, missing the consensus of $715.49 million....

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52. The company reported sales of $2.43 billion, up 6% year over year on a reported basis, 8% on constant...

Eli Lilly And Co (NYSE:LLY) will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours. The stock is up 14.35% over the past year, 14.79% YTD. Let’s examine the charts for Eli Lilly stock...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) reported a first-quarter EPS loss of 93 cents on Wednesday, down from a loss of 98 cents, beating the consensus of a $1.12 loss. Revenue increased 10% in the first quarter of 2025 to $132 million, beating the consensus of $125.32 million, driven by...

On Friday, AbbVie Inc (NYSE:ABBV) reported an adjusted EPS of $2.46, up 6.5% year over year and beating the consensus of $2.38. The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a reported basis (+9.8% on an operational basis), beating the consensus of $12.92 billion. It...

Merck & Co. Inc‘s (NYSE:MRK) M&A efforts will continue. That’s according to a Goldman Sachs analyst report, which details the company’s growth strategy. Analyst Asad Haider explained in a Friday note that Merck acknowledges that deal-making is getting more complex. However...

Merck & Co Inc (NYSE:MRK) will be reporting its first-quarter earnings on Thursday before the market opens. Wall Street expects earnings per share of $2.14 and revenue of $15.33 billion. The stock is down a painful 38.04% over the past year and has dropped 20.73% year-to-date. Even in the past...

Cantor Fitzgerald initiated coverage on Eli Lilly And Co (NYSE:LLY) on Monday, citing orforglipron data, which strengthens the case for obesity dominance. Last week, the U.S. drug giant reported topline Phase 3 results from the ACHIEVE-1 trial of orforglipron compared to placebo in adults with type...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the past 12 months. But with a 3.5% pullback in the past month, all eyes are now on its first-...

Eli Lilly & Co. (NYSE:LLY) shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14....

Last week, U.S. President Donald Trump disclosed plans for a “major tariff” on foreign pharmaceuticals. BofA Securities analyst said if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a “Section 232...